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Background: Yellow fever virus (YFV) belongs to the Flavivirus genus and causes an important disease. An alarming
resurgence of viral circulation and the expansion of YFV-endemic zones have been detected in Africa and South
America in recent years. NS5 is a viral protein that contains methyltransferase and RNA-dependent RNA polymerase
(RdRp) domains, which are essential for viral replication, and the interactions between NS5 and cellular proteins
have been studied to better understand viral replication. The aim of this study was to characterize the interaction of
the NS5 protein with eukaryotic translation initiation factor 3 subunit L (eIF3L) and to evaluate the role of eIF3L in
yellow fever replication.
Methods: To identify interactions of YFV NS5 with cellular proteins, we performed a two-hybrid screen using the
YFV NS5 RdRp domain as bait with a human cDNA library, and RNApol deletion mutants were generated and
analyzed using the two-hybrid system for mapping the interactions. The RNApol region involved was segmented
into three fragments and analyzed using an eIF3L-expressing yeast strain. To map the NS5 residues that are critical
for the interactions, we performed site-direct mutagenesis in segment 3 of the interaction domain (ID) and
confirmed the interaction using in vitro assays and in vivo coimmunoprecipitation. The significance of eIF3L for YFV
replication was investigated using eIF3L overexpression and RNA interference.
Results: In this work, we describe and characterize the interaction of NS5 with the translation factor eIF3L. The
interaction between NS5 and eIF3L was confirmed using in vitro binding and in vivo coimmunoprecipitation assays.
This interaction occurs at a region (the interaction domain of the RNApol domain) that is conserved in several
flaviviruses and that is, therefore, likely to be relevant to the genus. eIF3L overexpression and plaque reduction
assays showed a slight effect on YFV replication, indicating that the interaction of eIF3L with YFV NS5 may play a
role in YFV replication.
Conclusions: Although the precise function of eIF3L on interactions with viral proteins is not entirely understood,
these results indicate an interaction of eIF3L with YF NS5 and that eIF3L overexpression facilitates translation, which
has potential implications for virus replication.
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Yellow fever virus (YFV) is a mosquito-borne member
of the Flavivirus genus of the Flaviviridae family. YFV
infects humans and nonhuman primates and is a highly
pathogenic human virus [1,2]. Severe YF is a systemic viral
disease, presenting viremia, fever, prostration, hepatic,
renal, and myocardial injury, hemorrhage, and shock; 20
to 50% lethality is reported for severe cases. An alarming
resurgence of viral circulation and the expansion of YFV-
endemic zones have been detected in Africa and South
America in recent years, potentially leading to the outbreak
of urban epidemics [3]. Despite the existence of an efficient
vaccine, there is no antiviral drug to treat yellow fever or
other flaviviruses.
In most cases, the treatment of severe YF by supportive
care is essentially ineffective, and there is a clear need for
safe and effective drugs to treat patients during all
stages of this disease. Therefore, the target-based design
of inhibitors of Flavivirus replication may be a promising
strategy toward the development of selective anti-flaviviral
drugs [2,4].
The Flavivirus genome consists of an 11-kb positive-
strand RNA with 5′ and 3′ untranslated regions (UTRs)
and a single long open reading frame (ORF). Flaviviruses
produce a subgenomic, noncoding RNA (approximately
0.5 kb) that is derived from the 3′ UTR of the genomic
RNA (gRNA). The subgenomic Flavivirus RNA (sfRNA)
is a product of the incomplete degradation of gRNA,
which may involve cellular 5′-3′ exoribonuclease 1
(XRN1), a key enzyme in the cellular mRNA decay
pathway. sfRNAs are involved in viral replication,
cytopathicity, and pathogenicity and may play a role in
modulating host antiviral responses via RNA-mediated
pathways [5].
The translation of the Flavivirus gRNA produces a
polyprotein that is cleaved co- and post-translationally
by a combination of host and viral proteases into three
structural proteins that constitute the viral particle
(capsid, C; membrane precursor, prM; and envelope, E),
and seven nonstructural (NS) proteins (NS1, NS2A,
NS2B, NS3, NS4A, NS4B, and NS5), which are involved in
viral RNA replication, virus assembly, and the modulation
of host cell responses [2,4]. NS5 is the largest and most
highly conserved protein and contains two distinct enzym-
atic activities that are essential during viral replication.
Separated by an interdomain region, the S-adenosyl
methyltransferase activity is located at the N-terminus and
is responsible for capping the nascent RNA, and the
RNA-dependent RNA polymerase (RdRp) activity is found
at the C-terminus and is responsible for replicating the
viral RNA genome [3,6].
Flaviviruses enter their target cells by receptor-mediated
endocytosis, whereby the acidic environment triggers major
conformational changes in their envelope glycoprotein (E),inducing the fusion of the viral and host cell membranes.
The RNA released into the cell encodes a polyprotein
precursor that is processed as described above. During
these processes, the (+) ssRNA viral genome acts as a
template for (i) the synthesis of the intermediate (−)
ssRNA strand by NS5 RdRp, which in turn acts as template
solely for the synthesis of (+) ssRNA genomic RNAs
(again by the NS5), and (ii) the synthesis of the viral
polyprotein. Immature, noninfectious virions assemble
within the endoplasmic reticulum (ER): the viral RNA is
complexed with the C protein and packaged into an ER-
derived lipid bilayer containing heterodimers of the prM
and E proteins. After transport through the host secretory
pathway and virion maturation in the Golgi, mature infec-
tious particles are then released by exocytosis [4,7].
Numerous host gene products and pathways have
recently been implicated in the replicative cycle of
flaviviruses; however, the biological relevance of many of
these interactions is not clear [7]. Indeed, the detailed
analysis of these interactions might provide a better
understanding of viral replication and lead to the rational
development of drugs [8,9].
The 67-kDa L subunit of human eukaryotic translation
initiation factor 3 (eIF3L) is one of the subunits of the
mammalian translation initiation factor eIF3 [10]. The
eIF3 factor plays a central role in translation initiation
by recruiting the 40S ribosomal subunit and keeping it
dissociated from the 60S subunit and by promoting the
association of the former with mRNA and initiator
Met-tRNA [10]. In addition, eIF3 interacts with other
initiation factors involved in start codon selection;
however, the molecular mechanisms by which eIF3 exerts
these functions are poorly understood [11]. Masutani and
colleagues (2007) demonstrated that the L subunit of eIF3
is dispensable in the formation of active eIF3 complexes
during ribosomal recruitment, suggesting that eIF3L likely
increases the physical stability of the eIF3 complex by pro-
viding intersubunit connections [12]. Furthermore, Seither
and colleagues (2001) reported that eIF3L functions as an
accessory protein of cellular Pol I (PAF67), suggesting that
the association of eIF3L with the enzyme endows Pol I
with the capability to assemble into a productive
transcription initiation complex at the rDNA promoter.
Despite these findings, the function of eIF3L in viral
replication is unknown.
In this work, we describe and characterize the interaction
of NS5 with the translation factor eIF3L, as confirmed by
in vitro binding and in vivo coimmunoprecipitation assays.
This interaction occurs in a region (the interaction domain
of RNApol domain) that is conserved in several flaviviruses
and that is, therefore, likely to be relevant to the genus.
Although eIF3L overexpression and plaque reduction
assays (using an YFV replicon [13]) demonstrated a
slight (if any) inhibition of YFV replication, we were able
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lation, with potential implications in viral replication.
Results
Identification of cellular proteins interacting with YFV NS5
To identify cellular proteins interacting with YFV NS5, a
yeast two-hybrid screen was performed using the RNA
polymerase domain of NS5 (amino acids 300 to 905) as
bait against a HeLa cell cDNA library. Thirty-five positive
clones were obtained from 3.8 × 104 independent yeast col-
onies. DNA sequence analysis and the BLASTN algorithm
were employed to analyze the sequence data, resulting in
the identification of eIF3L as a YFV NS5-interacting
protein, which was detected in 3 of the 35 sequenced
clones.
Confirmation of the interaction between the RNApol
domain of NS5 and eIF3L
To confirm the interaction of the RNApol domain with
eIF3L and to exclude the possibility of false-positive
clones, plasmids pGBKT7-RNApol and pACT2-eIF3L
were cotransfected into yeast and selected by the activation
of the reporters HIS3 and ADE2. The transformants
were selected on SD medium (−His, -Leu, and -Trp) and
confirmed on SD medium (−Ade, -His, -Leu, and -Trp).
The co-transformants grew on control drop-out medium
(SD) plates lacking leucine (−Leu) and tryptophan (−Trp),
as shown in Figure 1. The growth on plates lacking
histidine (−His) and adenine (−Ade) was indicative of
a positive interaction, as shown between the RNApol
domain and eIF3L.
Mapping the eIF3L-binding domain of RNApol
A series of RNApol deletions were generated to map
the interaction between the RNApol domain and eIF3LFigure 1 YFV NS5 (RNApol)-human eIF3L interaction in a yeast two-h
RNApol (or the empty or Lamin C human protein BD vector) and pACT2-eI
interaction was identified by the growth of transformants on SD medium (
activation of the reporter genes HIS3 and ADE2. C-, negative control; C+, po
dilutions of sample.(Figure 2), and these RNApol variants were tested for
interactions with eIF3L by the activation of HIS3 and
ADE2 in yeast. As shown in Figure 2, the RNApol
deletion mutants Δ300-368, Δ376-905, Δ450-905, Δ525-
905, Δ600-905, Δ675-905, and Δ751-905 interacted with
eIF3L, indicating that the interaction occurs within an
80-amino acid region (368 to 448) of RNApol known as
the interaction domain (ID).
The terminal region of the interaction domain is essential
for the interaction with eIF3L
For a more precise mapping of the interaction, the inter-
action domain was divided into three fragments: ID1
(368 to 412), ID2 (385 to 431), and ID3 (431 to 448).
The fragments were cloned and transformed into
yeast along with eIF3L. As shown in Figure 3, a po-
sitive interaction occurs between the N-terminal third
portion (approximately 17 amino acids) of ID and
eIF3L.
Mapping the residues of the terminal region of the
interaction domain that are critical for the interaction
with eIF3L
Given the previous identification of segment 3 of the
ID as the site of interaction with eIF3L, this region
was subjected to site-direct mutagenesis to identify
the NS5 residues that are critical for the observed
interaction.
Mutants ID (F431A/W432A/V435A), ID (D436N),
ID (D436S), and ID (R439A/H442A) were tested for in-
teractions with eIF3L, as described above. Yeast cells
expressing mutants ID (D436N), ID (D436S), and ID
(R439A/H442A) interacted with eIF3L and are, therefore,
not likely to be critical for the interaction. In contrast,
no growth of yeast containing the mutant ID (F431A/ybrid system. Yeast strain AH109 was co-transformed with pGBKT7-
F3L (or the empty or SV40 large T-antigen AD vector). The specific
−LEU, -TRP, -HIS) and SD medium (−LEU, -TRP, -HIS, -ADE) with the
sitive control; N, normalized original culture sample; 1–4, 10-fold serial
Figure 2 Determination of the YFV NS5 domain responsible for the interaction with eIF3L. The figure shows a representation of RNApol
NS5 YFV and its fragments, with deletions (1–14) used to map the interaction domain with the eIF3L protein in the yeast two-hybrid system. The
yeast was co-transformed with the pGBKT7-deletion constructs and pACT2-eIF3L. The interaction occurs between amino acids 368 and 448
(interaction domain, the region in black in the schematic representation), which was identified by the growth of transformants on SD medium
(−LEU, -TRP, -HIS) and SD medium (−LEU, -TRP, -HIS, -ADE) with the activation of the reporter genes HIS3 and ADE2. C-, negative control; C+,
positive control; N, normalized original culture sample; 1–4, 10-fold serial dilutions of sample.
Morais et al. Virology Journal 2013, 10:205 Page 4 of 13
http://www.virologyj.com/content/10/1/205W432A/V435A) and eIF3L was observed on plates lacking
histidine (−His) (Figure 4). This triple alanine-substitution
mutation is within the FWELV region of ID, indicating
that the FWELV region may be critical for the interaction
with eIF3L.Figure 3 The eIF3L protein specifically interacts with the N-terminal reg
with the pGBKT7 segments and pACT2-eIF3L (or the empty or large T-antigen
detected by activation of the reporter genes HIS3 and ADE2, which led to the
medium (−LEU, -TRP, -HIS, -ADE). C-, negative control; C+, positive control; N,Interaction of eIF3L with the interaction domains of other
flaviviruses
To assess the potential interaction of eIF3L with other
flaviviruses, the ID homolog from dengue virus 4, dengue
virus 3, and Saint Louis encephalitis (SLE) virus wereion of the NS5 YFV interaction domain. The yeast was co-transformed
SV40 AD vector). Segment 3 NS5 (ID) and eIF3L interaction was
growth of transformants on SD medium (−LEU, -TRP, -HIS) and SD
normalized original culture sample; 1–4, 10-fold serial dilutions of sample.
Figure 4 The mapping of the terminal region residues of the interaction domain using the yeast two-hybrid system indicates a critical
interaction with eIF3L. The yeast was co-transformed with the mutant pGBKT7 constructs and pACT2-eIF3L. A positive interaction is shown by
the activation of the reporter gene HIS3 in the interaction of eIF3L with the mutants ID (D436N), ID (D436S), and ID (R439A/H442A), indicating
that the mutations are not critical for the interaction. A negative interaction between mutant ID (F431A/W432A/V435A) and eIF3L is indicated by
the absence of growth on plates lacking histidine (−His). C-, negative control; C+, positive control; N, normalized original culture sample; 1–4,
10-fold serial dilutions of sample.
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actions for pGBKT7-ID (D3), pGBKT7-ID (D4), and
pGBKT7-ID (SLE) with eIF3L were demonstrated by
growth on plates lacking histidine (−His) and adenine
(−Ade) (Figure 5), the IDs from dengue virus 4, dengue
virus 3, and Saint Louis encephalitis virus also interact
with eIF3L.
YFV NS5 (ID) binds to eIF3L in vitro
The interaction between the YFV NS5 interaction domain
and eIF3L was confirmed using a glutathione S-transferase
(GST) pull-down assay. These assays were performed using
purified GST-ID and GST bound to glutathione-Sepharose
beads in combination with Flag-tagged eIF3L produced in
HeLa cells. As shown in Figure 6, Flag-eIF3L interactedFigure 5 The interaction domains of other flaviviruses interact with e
(Flavivirus members dengue virus types 3 and 4 and St. Louis encephalitis)
The interaction domains of other flaviviruses (DENV types 3 and 4 and SLE)
activation of the reporter genes HIS3 and ADE2. C-, negative control; C+, po
dilutions of sample.with the GST-ID fusion protein (Figure 6, column 3) but
not with the negative GST control (Figure 6, column 2).YFV NS5 interacts with eIF3L in mammalian cells
Coimmunoprecipitation assays were performed to confirm
that the YFV NS5 protein interacts with eIF3L in mamma-
lian cells. Vero cells were transfected with Flag-eIF3L and
infected with YFV. Cell lysates containing both NS5 and
Flag-eIF3L were incubated with anti-Flag beads, and the
eluates were subjected to western blot analyses. As shown in
Figure 7B, YFV NS5 was efficiently coimmunoprecipitated
with Flag-eIF3L. In contrast, YFV NS5 was not precipi-
tated in the absence of Flag-eIF3L. Similarly, no YFV
NS5-reactive species were detected in the cell lysatesIF3L. The yeast cells were co-transformed with pGBKT7-ID
and pACT2-eIF3L (or the empty or large T-antigen SV40 AD vector).
present a positive interaction with the eIF3L protein through the
sitive control; N, normalized original culture sample; 1–4, 10-fold serial
Figure 6 In vitro analyses of the YFV NS5 (ID)-eIF3L
interaction. (A) pGEX 5X1-ID plasmid, the GST-fused ID (33 kDa)
expressed in E. coli BL21 (DE3). (B) Control GST (26 kDa) expressed
in E. coli BL21 (DE3). (C) HeLa cells were transfected with a
plasmid expressing Flag-tagged eIF3L (67 kDa) (column 1). This
protein was incubated with resin-bound GST or GST-ID. After the
samples were washed, the resin-bound proteins were resolved by
SDS-PAGE and then analyzed by a western blot assay using an
anti-Flag antibody. The interaction of Flag-eIF3L with GST-ID
(column 3) was confirmed, without a nonspecific interaction with
GST (column 2).
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indicate that YFV NS5 can interact with eIF3L in vivo.The potential role of eIF3L in yellow fever virus
replication
To establish the significance of these interactions within
a physiological context, we evaluated the role of eIF3L
using overexpression and RNA interference assays.Figure 7 Coimmunoprecipitation of YFV NS5 and eIF3L in mammalian
Flag-tagged eIF3L and infected with YFV strain 17D at an M.O.I. of 5. At 48
immunoprecipitation using anti-Flag M2 affinity gel beads. The coimmunop
anti-YFNS5 antibody. (A) Cell lysates immunoprecipitated using the anti-Fla
cells; eIF3L+YFV, eIF3L immunoprecipitated from transfected and infected c
non-transfected cells. (B) Coimmunoprecipitation of the NS5 protein with t
infected cells (98 kDa); eIF3L+YFV, coimmunoprecipitation of YFV NS5 with
not precipitated in non-transfected cells.For overexpression, BHK-21-Rep-YFV17D LucNeoIres
cells, a stable bicistronic dual-reporter YFV replicon cell
line expressing the neomycin phosphotransferase resistance
gene and the reporter gene firefly luciferase [13], were
used. The cells were transfected with the pCDNAFlag-
eIF3L plasmid or an empty vector. After 48 h, the cells
were collected for a western blot analysis and luciferase
activity assays. eIF3L overexpression relative to cells
transfected with the empty vector or to untransfected
cells is shown in Figure 8A (column 1). The levels of
luciferase activity in the cell lysates were significantly re-
duced by 50% compared to the controls (Student’s t-test;
p<0.05) (Fig. 8B). An shRNA against YF [14] was used as a
positive control.
Furthermore, eIF3L expression was downregulated in
HEK293T cells infected with pseudotyped lentiviral
particles containing specific pLKO.1-eIF3LshRNA1 or
pLKO.1-eIF3LshRNA2 or negative controls. In the
silenced cells, the levels of viral RNA (as determined
by real-time PCR) were not significantly reduced in
comparison to the controls (Figure 8C).
We also overexpressed eIF3L in Vero cells and infected
the cells with 50 PFU of YFV17D virus. At 48 h after
infection, a slight inhibition of yellow fever virus replication
(but without statistical significance) was observed in the
pCDNAFlag-eIF3L-transfected cells compared to the
controls (Figure 8D). In addition, we also overexpressed
eIF3L in Vero cells and infected them with a multiplicity
of infection (M.O.I.) of 1 for the YFV 17D virus. Super-
natants were collected at 6, 12, 24, and 48 h.p.i., and
qRT-PCR was performed. Similar to the above results,
the levels of viral RNA were not significantly reduced in
the pCDNAFlag-eIF3Ltransfected cells (Figure 8E).
As it can be argued that the addition of eIF3L can inhibit
translation by itself (i.e., as very little is know regarding thecells. Vero cells were transfected with a plasmid expressing
h post-infection, the cells were lysed and subjected to
recipitated proteins were analyzed by a western blot assay using an
g antibody. Input, positive control eIF3L (67 kDa) from transfected
ells; YFV, infected and non-transfected cells; MOCK, non-infected and
he anti-YFV NS5 antibody. Input, positive control YFV NS5 from
Flag-eIF3L showing a positive interaction; YFV, MOCK, YFV NS5 was
Figure 8 Effect of eIF3L on yellow fever virus replication. (A) eIF3L overexpression in BHK21-rep-YFV17D LucNeoIres cells at 48 h post-transfection
using an anti-Flag antibody or anti-GAPDH antibody as a control. eIF-pCDNAFlag, overexpressing eIF3L; pCDNAFlag, empty vector control; MOCK,
control cells. (B) Luciferase activity at 48 h transfection with eIF3L in BHK21-rep-YFV17D LucNeoIres cell lysates; MOCK, control cells; pCDNAFlag, empty
vector control; eIF3L-pCDNAFlag, eIF3L overexpression; siRNA NS1, positive control. *Significantly different between the RNAi NS1 and mock samples;
**significantly different between the pCDNAFlag-eIF3L and mock samples. (C) Quantification of viral RNA transcripts at 24 and 48 h post-infection with
pseudotyped lentiviral particles using real-time PCR analysis. pLKO.1-eIF3LshRNA1, eIF3L silenced and infected cells; pLKO.1-eIF3LshRNA2, eIF3L
silenced and infected cells; pLKO, empty vector control-infected cells; non-target, plasmid control non-target infected cells; YFV, infected cells; MOCK,
control cells. (D) The plaque reduction assay indicates a discrete reduction in viral replication. (E) Quantification of viral RNA in Vero cell supernatants
overexpressing eIF3L at 6, 12, 24, and 48 h post-infection.
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also verified the effect of eIF3L expression on general
translation. Thus, the plasmid pGL3Promoter (Promega)
was co-transfected into HeLa cells with eIF3L in a dose-
dependent manner. As can be observed in Figure 9, eIF3L
in fact facilitated translation in the same amount that
inhibited the luciferase-YFV replicon.Discussion
Although numerous host gene products and pathways
have recently been implicated in the replicative cycle of
flaviviruses, their biological relevance remains unclear
[7]. Based on previous demonstrations of interactions of
the NS5 proteins of other Flavivirus with host cellular
proteins [15-22], in the present study, we analyzed YFV
Figure 9 Effect of eIF3L expression on general translation. The
HeLa cells were cotransfected with pCDNAFlag-eIF3L and pGL3
promoter plasmids in a dose-dependent manner. After 48 h, the
cells were lysed, and the supernatant was used for luciferase
activity assays.
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host proteins that interact with the YFV NS5 RdRp domain
and assessing their functions in viral replication. These
experiments were performed only with YFV NS5 RdRp
because the methyltransferase domain is likely responsible
for the cytotoxic effect that we observed in yeast (data
not shown).
Using yeast two-hybrid, in vitro binding, and coim-
munoprecipitation assays, we demonstrated that the
YFV NS5-RdRp protein interacts with eukaryotic transla-
tion initiation factor 3 subunit L (eIF3L). Although eIF3L
has an essential cellular function, its significance in viral
replication remains to be determined, and even its cellular
role is uncharacterized.
During viral replication, the virus enters the cell, the
nucleocapsid disassembles, and replication then proceeds
with the immediate translation of the genome. The 5′-end
of the (+) ssRNA genome is decorated by an RNA cap
structure (N7meGpppA2’Ome-RNA) that plays an essential
role in the initiation of translation and in protecting
the viral RNA from degradation by endogenous RNA
exonucleases [4]. The virus presumably borrows host
eukaryotic translation initiation factors (eIFs) to initiate
translation [3]. Indeed, previous studies have demonstrated
the association of eIFs, including eIF3, in viral replication
[23-25] and have also reported the involvement of other
proteins, such as eIF3F, with this complex to inhibit viral
replication [24].
Schoggins et al. (2011) used a screening approach
along with eIF3L overexpression to demonstrate a
modest inhibitory potential (approximately 10%) on
YFV replication [26]. Within a physiological context,
eIF3L expression is downregulated in peripheral blood
mononuclear cells after vaccination with the yellowfever 17D virus [27]. These findings suggest that, after
entry of the virus into the cells, YFV can induce the
downregulation of eIF3L as a way to escape the host’s
immune system.
In this study, we have demonstrated that eIF3L over-
expression in mammalian cells results in a significant
decrease in luciferase activity in assays. However, we used
a cell lineage carrying a yellow fever virus replicon with
two different points of translation, a 5′ cap end and an
internal ribosome entry site (IRES) element; eIF3 complex
proteins were involved in their translation in both cases.
The eIF3L protein is a subunit of the eIF3 translation
complex, and its overexpression could affect replicon
translation, with a downregulation of luciferase activity
though without inhibiting viral replication. Therefore, to
determine the direct effect of eIF3L on replication, a
plaque reduction assay and quantification of viral RNA
after overexpressing or silencing eIF3L were performed.
Although the levels of viral RNA were not significantly
reduced in the silenced cells, the plaque reduction assay
and qRT-PCR after overexpression displayed modest
levels of inhibition (but not statistically significant) on
viral replication. It is important to note that eIF3L
overexpression did not affect the global synthesis of
proteins in the cell, which was shown by the endogenous
control of GAPDH, and that the same concentration
that facilitated translation inhibited yellow fever virus
replication (Figure 9).
Therefore, our results are in agreement with the
findings in the literature, though further studies will be
necessary to understand the mechanisms involved in
viral replication.
Soon after translation, NS5 RdRp initiates the synthesis
of full-length negative-sense RNA copies from the genome
template that are transcribed to produce progeny positive-
sense RNA genomes [3]. Mammalian RNA polymerase I
(Pol I) is a multisubunit enzyme that interacts with
accessory proteins, PAFs (polymerase-associated factors),
including eIF3L (PAF67), and the available data suggest
the involvement of these proteins in the initiation of
transcription [28]. Yuan et al. (2002) demonstrated that
the transcription factor TIF-IA is strongly associated
with eIF3L (PAF67); TIF-IA is also associated with a
subpopulation of Pol I to form the transcriptionally
active enzyme and is a target of diverse signaling pathways
[29]. Therefore, eIF3L binding to TIF-IA may be a target
of regulatory pathways in association with the YFV NS5
RNA polymerase.
Using two-hybrid assays, we demonstrated that the
interaction occurred within an 80-amino acid region
(interaction domain, ID) of RNApol. As reported previously
[30], the production of a homology model for the RNA
polymerase domain of the YFV NS5 protein showed that
this region of interaction (ID) is exposed and potentially
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that ID from the dengue 4, dengue 3, and Saint Louis
encephalitis viruses interact with eIF3L, suggesting that
this interaction is important for other members of the
genus. Accordingly, when the YFV sequence was compared
to the sequences of other flaviviruses, a region of homology
from residues 20 to 80 was identified [30]. Mutations in
the FWELV motif of ID abolished the interaction with
eIF3L, suggesting that the amino acids FWELV are critical
for the ID interaction with eIF3L. The three mutations
produced in this region may have led to changes in protein
conformation, preventing possible interactions with other
cellular proteins. However, the data from another study in
our laboratory [30] have demonstrated that the same
mutations do not affect the interaction of the ID domain
with the cellular small ribonucleoprotein polypeptide A
(U1A), indicating that the structure of the domain is not
significantly altered and is potentially capable of interacting
with other molecules.
Conclusion
In summary, we identified that the eIF3L protein interacts
with the yellow fever NS5 protein. Although the precise
function of eIF3L in the viral life cycle is still not entirely
understood and the results for viral replication are incon-
clusive, we were able to demonstrate that eIF3L over-
expression facilitates translation and that the interaction
of eIF3L with YF NS5 may have an important role in viral
replication. Further studies on this interaction may lead




For the yeast two-hybrid system, the plasmids pGBKT7
and pACT2 (Clontech Inc., USA) were used as the
sources of the GAL4 DNA-binding domain (BD) and
GAL4 transcriptional activation domain (AD), respectively.
The plasmid pACNR-FLYF17D [31] contains the complete
genome of YFV and was kindly provided by Charles Rice
(Rockefeller University, USA). For the construction of
pGBKT7-RNApol, the RNApol domain (corresponding to
amino acids 300 to 905 of YFV NS5 [32]) was amplified by
PCR using the plasmid pACNR-FLYF17D. Oligonucleotides
5′-TATGAATTCAATGACAACCCTACAGGACC-3′ and
5′-TATCTGCAGTCAGATAAGCTCACCCAGTTGC-3′
were used as the plus- and minus-strand DNA primers,
respectively. The PCR products were digested with EcoRI
and PstI and cloned into the corresponding sites of the
pGBKT7 plasmid. For mapping the interaction, pGBKT7-
RNApol deletion mutants, Δ300-367, Δ300-441, Δ300-517,
Δ300-595, Δ300-668, Δ300-740, Δ300-814, Δ825-905,
Δ751-905, Δ676-905, Δ604-905, Δ526-905, Δ450-905, andΔ376-905, were prepared by PCR using pACNR-FLYF17D
as a template and the following primers: 5′-TATGAATT
CGCGGGAACTAGGAAGATC-3′ (forward, Δ300-367),
5′- TATGAATTCCACCAACAAGGCAGGTGT-3′ (for-
ward, Δ300-441), 5′-TATGAATTCGTG ATCAGAGAC
CTGGCT-3′ (forward, Δ300-517), 5′-TATGAATTCCGA
CGAGACCAGAGA GG-3′ (forward, Δ300-595), 5′-TA
TGAATTCGTGGTCCGGCCCATC-3′ (forward, Δ300-
668), 5′- TATGAATTCGGAAGGGTGTCTCCAGG-3′
(forward, Δ300-740), 5′-TATGAATTCGTG TGGAAC
AGAGTATGG-3′ (forward, Δ300-814), 5′-TATCTGCA
GTCACCATACTCTGTT CCACAC-3′ (reverse, Δ825-
905), 5′-TATCTGCAGTCATCCTGGAGACACCCTTC
C-3′ (reverse, Δ751-905), 5′-TATCTGCAGTCAGATG
GGCCGGACCAC-3′ (reverse, Δ676-905), 5′-TATCTG
CAGTCATCCTCTCTGGTCTCGTCG-3′ (reverse, Δ604-
905), 5′-TAT CTGCAGTCAAGCCAGGTCTCTGATCA
C-3′ (reverse, Δ526-905), 5′-TATCTGCAGTCA ACACC
TGCCTTGTTGGTG-3′ (reverse, Δ450-905), and 5′-TAT
CTGCAGTCAGATCTTCCT AGTTCCCGC-3′ (reverse,
Δ376-905). The PCR products were digested with EcoRI
and PstI and cloned into the corresponding sites of the
pGBKT7 plasmid. pGBKT7-ID, with an interaction do-
main sequence corresponding to amino acids 368 to 448
of the RNApol domain, was generated by PCR using the
plasmid pACNR-FLYF17D as a template and the following
primers: 5′-TATGAATTCGCGGGAACTAGGAAGATC-
3′ (forward) and 5′-TATCTGCAGTCAACACCTGCCTT
GTTGGTG-3′ (reverse). The PCR products were digested
with EcoRI and PstI and cloned into the corresponding
sites of the pGBKT7 plasmid. For the construction of
pGBKT7-ID (1) (corresponding to amino acids 368 to 412
of the interaction domain), pGBKT7-ID (2) (amino acids
385 to 431 of the interaction domain), and pGBKT7-ID
(3) (amino acids 431 to 448 of the interaction domain), we
performed PCR amplifications using pACNR-FLYF17D as
the template and the following primers: ID (1) 5′-GCG
GGAAACTAGGAAGATC-3′ (forward) and 5′-AGCTC
CAATGGCTGCATGACTTCG-3′ (reverse), ID (2) 5′-
CTGGCCAGAGAAAAGAAACCCC-3′ (forward) and 5′-
CTTTGGGTCTTGGACAGC-3′ (reverse), ID (3) 5′-TTC
TGGGAACTGGTGGATGAA-3′ (forward) and 5′-ACA
CCTGCCTTGTTGGTG-3′ (reverse). The PCR products
were digested with EcoRI and PstI and cloned into the
corresponding sites of the pGBKT7 plasmid.
Plasmids pGBKT7-ID (D3), pGBKT7-ID (D4), and
pGBKT7-ID (SLE) were generated using dengue 3
(RPDen06/41) (AY858045), dengue 4 (Boa Vista)
(AY762085) and SLEV (BeH 355964) (AY632544) as
the template and primers: ID (D3) 5′-TATGGATCCT
ATGGCTTTGGAGAACCCTGGG-3′ (forward, BamHI)
and 5′-CTCCTGCGAACACTTGCCCAATTTGTGGAG
TTC-3′ (reverse, PstI); ID (D4) 5′-TATGAATTCTGGCT
GTGGGCCCTCCTTGG-3′ (forward, EcoRI) and 5′-TTA
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(reverse, PstI); and ID (SLE) 5′-TATGGATCCTAT
GGCTGTGGGACTTCGTTGC-3′ (forward, BamHI) and
5′-CTCCTGCAAGACACTCTCCTTTAAGATGGGCTT
C-3′ (reverse, PstI). The PCR products were digested
and cloned into the corresponding sites of the pGBKT7
plasmid.
All amplicons were sequenced using Big Dye v3.1 and
an ABI3130 DNA sequencer (Applied Biosytem, Foster
City, CA).
The plasmid pSGFlag-eIF3L (kindly provided by
Pierre Jalinot, Laboratorie de Biologie Moleculaire de la
Cellule, Lyon, France) [10] codes for the eIF3L protein
and was used for the in vitro pull-down and in vivo
coimmunoprecipitation assays.
The plasmids pLKO.1-eIF3L shRNA1 (5′ CCGGCCT
GGTAGACAAATCCAACATCTCGAGATGTTGGATT
TGTCTACCAGGTTTTTG 3′) pLKO.1-eIF3L shRNA2
(5′CCGGACACACATTCAGGAACCTGTTCTCGAGA
ACAGGTTCCTGAATGTGTGTTTTTTG 3′) (Sigma)
(MISSION shRNA plasmid DNA, NM_016091.2-786,
NM_016091.2-1791, respectively), VSVG, and pCMV
R8.74 (provided by Renato Santana de Aguiar, Mole-
cular Virology Laboratory, Rio de Janeiro, Brazil) were
used in the construction of pseudotyped lentiviral
particles.
The pGL3 promoter and pGL3 basic vector (provided by
Thomas Khristie, Bethesda, USA), containing the gene for
luciferase expression, were used for eIF3L overexpression
during translation.Site-directed mutagenesis
Site-direct mutagenesis was performed using the Quick
Change Site Direct Mutagenesis kit (Stratagene, USA) and




CCTTTGGGTCTTGGACAG-3′ (reverse); for ID (D436N),
5′-GTTCTGGGAACTGGTGAATGAAGAAAGGAAGC
TGC-3′ (forward) and 5′-GCAGCTTCCTTTCTTCAT
TCACCAGTTCCCAGAAC-3′ (reverse); for ID (D436S),
5′-GTTCTGGGAACTGGTGAGTGAAGAAAGGAAGC
TGCAAC-3′ (forward) and 5′-GGTGCAGCTTCCTTTC
TTCACTCACCAGTTCCCAGAAC-3′ (reverse); and for
ID (R439A/H442A), 5′-GGAACTGGTGGATGAAGAAG
CGAAGCTGGCCCAACAAGGC-3′ (forward) and 5′-G
CCTTGTTGGGCCAGCTTCGCTTCTTCATCCACCAG
TTCC-3′ (reverse). The PCR products were digested with
DpnI to eliminate the methylated parental DNA tem-
plates, and the correct mutant clones were verified by
DNA sequencing and then subcloned back into a new
pGBKT7 vector.Yeast two-hybrid screen
The yeast strain Saccharomyces cerevisiae AH109 (BD
MATCHMAKER GAL4 Two-Hybrid System 3,
Clontech, USA) was used for the two-hybrid screen. The
bait plasmid pGBKT7-RNApol and the pACT2 HeLa
cell cDNA library (Clontech, USA) were sequentially in-
troduced into the yeast cells using the EZ-Yeast Trans-
formation kit - Single Vector Transformation protocol
(Q.BIO gene, USA). Transformants were initially se-
lected on SD medium (−His, -Leu, and -Trp) and con-
firmed on SD medium (−Ade, -His, -Leu, and -Trp). The
SV40 large T-antigen and p53 were used as positive
interaction controls, whereas Lamin C was used as a
negative control. The filter lift assay was performed with
isolated colonies for β-galactosidase activity. The prey
plasmids were selected from yeast colonies and by pro-
viding a positive signal, according to the manufacturer’s
recommendations. False positives were eliminated by
retransforming the isolated plasmids into the AH109
strain containing pGBKT7-RNApol. Plasmid DNA was
isolated (RPM Yeast Plasmid Isolation kit, Q.BIO gene,
USA) from the positive clones and sequenced according
to the manufacturer’s recommendations. To demon-
strate the interaction of RNApol with eIF3L, plasmids
pGBKT7-RNApol and pACT2-eIF3L were cotrans-
fected into yeast using the lithium acetate method.
Transformants were selected on SD medium (−His, -Leu,
and -Trp) and confirmed on SD medium (−Ade, -His, -
Leu, and -Trp).
Interaction mapping
For mapping the interactions, pGBKT7-RNApol deletion
mutants were transfected into yeast containing pACT2-
eIF3L and selected as described. Conversely, the RNApol
region of the interaction (the interaction domain) was
divided into three fragments, and the plasmids
pGBKT7-ID (1), pGBKT7-ID (2), and pGBKT7-ID (3)
were transfected into yeast containing pACT2-eIF3L.
Site-direct mutagenesis was performed in segment 3 of
ID to map the NS5 residues that are critical for its inter-
action with eIF3L. Plasmids pGBKT7-ID (FWELV),
pGBKT7-ID (NEE), pGBKT7-ID (SEE), and pGBKT7-ID
(RKLH) were analyzed as described above. To analyze
the possible interaction of eIF3L with the interaction do-
mains of other flaviviruses, the ID from the dengue 2,
dengue 3, and Saint Louis encephalitis viruses were also
tested using plasmids pGBKT7-ID (D3), pGBKT7-ID
(D4), and pGBKT7-ID (SLE), respectively.
Cells and viruses
HeLa cells (human epithelial cervical cancer) were
grown in Dulbecco’s Modified Eagle’s medium (DMEM)
containing 10% fetal bovine serum (FBS), 100 U/ml of
penicillin, and 100 U/ml of streptomycin. Vero cells
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essential medium (MEM) containing 10% FBS, 100 U/ml
of penicillin, and 100 U/ml of streptomycin. The BHK-
21-Rep-YFV17D LucNeoIRES cell line containing the
YFV bicistronic replicon (provided by Laura Gil, Aggeu
Magalhães Research Center, Fiocruz, Brazil) was grown
in minimum essential medium (MEM) containing 10%
FBS, 100 U/ml of penicillin, 100 U/ml of streptomycin,
and 500 μg/ml G418. The cells were maintained at 37°C
in a humidified atmosphere containing 5% CO2. Yellow
fever virus strain 17D (Fiocruz, Brazil) was expanded in
C6/36 cells. The infected tissue culture supernatant was
used as the source of virus after the determination of
the viral titers.
Recombinant protein purification
pGEX 5X1-ID and pGEX 5X1, the GST-fused ID and con-
trol GST, respectively, were expressed in E. coli BL21
(DE3) (Stratagene, USA). Briefly, 500-ml cultures were
induced for 3 h with isopropyl-β-D-thiogalactopyranoside
(1 mM) at 37°C, lysed in buffer (10 mM Tris–HCl [pH
8.0], 150 mM NaCl, 1 mM EDTA, 1 mM dithiothreitol,
1% Triton X-100, and 2 mM benzamidine), and sonicated
4 times (20 s each). After centrifugation, the supernatants
were applied to a glutathione-Sepharose 4B column (GE
Healthcare, Brazil) according to the manufacturer’s rec-
ommendations. Fractions containing GST-ID or GST were
concentrated using a Centricon filter (Millipore, USA).
In vitro binding assay
For the in vitro binding assays, 10 μg of GST or GST-ID
was bound to glutathione-Sepharose 4B (50% slurry)
in PBS for 1 h (4°C). After four washes with 1 ml
phosphate-buffered saline (PBS) and a final wash with
lysis buffer (50 mM Tris–HCl [pH 7.5], 150 mM NaCl,
0.5% NP-40, 1 mM sodium fluoride, 0.2 mM sodium
orthovanadate, 10 mM β-glycerophosphate, and protease
inhibitor cocktail Mini complete Roche®), 600 μg of ex-
tract derived from HeLa cells transfected with the
eIF3L-pSGFlag plasmid was added and incubated for 2 h
(4°C). The unbound fractions were collected, and the
beads were washed four times with 1 ml of lysis buf-
fer. The bound fraction was eluted by incubation with
SDS sample buffer and separated using 10% SDS-
polyacrylamide gels, followed by immunoblotting with
anti-Flag antibodies (1:1000; Sigma, USA). Antibody bind-
ing was detected using the Super Signal West Dura Pico
system (Pierce Biotechnology, USA) and analyzed using a
Kodak Gel Logic 2200 Image Station (Kodak, USA).
Coimmunoprecipitation
Coimmunoprecipitations were performed using anti-Flag
M2 Affinity gel (Sigma, USA). Vero cells were transiently
transfected with pSGFlag-eIF3L; after 24 h, the cells wereinfected with YFV strain 17D at an M.O.I. of 5 and incu-
bated in DMEM medium without FBS for 2 h. The
infected cells were washed with PBS and reincubated in
DMEM medium supplemented with 1% FBS for 48 h in
the presence of 5% CO2. Non-transfected and non-
infected Vero cells were used as the controls. The cells
were harvested in lysis buffer (50 mM Tris–HCl [pH 7.5],
150 mM NaCl, 0.1% NP-40, 5% glycerol, 1 mM sodium
fluoride, 0.1 mM sodium orthovanadate, 10 mM β-gly-
cerolphosphate, and protease inhibitor cocktail Mini
complete Roche®). Equal amounts of protein extracts were
subjected to immunoprecipitation for 3 h (4°C) using anti-
Flag M2 Affinity gel beads. After incubation, the beads
were washed four times with TBS buffer (50 mM Tris–
HCl [pH 7.4] and 150 mM NaCl). The antibody-protein
complexes were then resolved by SDS-PAGE, and the
YFV NS5 protein was identified by western blotting using
an anti-YFNS5 (1:4000) antibody, a kind gift of Charles M.
Rice, Rockefeller University.
Overexpression experiments and luciferase activity assays
BHK21-Rep YF17D LucNeoIres cells that were 70% con-
fluent were transfected using the Lipofectamine™ 2000 re-
agent (Invitrogen, USA) according to the manufacturer’s
recommendations. The empty vector and untransfected
cells were used as the negative controls; RNAi against
NS1 YFV [14] was used as a positive control. After 48 h of
transfection, the cells were lysed by the addition of Cell
Culture Lysis Buffer (Promega, USA), followed by incuba-
tion at room temperature for 5 min. The cell extracts were
centrifuged at 12,000 × g for 15 s (room temperature).
The luciferase assays were performed using 10 μl of cell
supernatants mixed with 100 μl of the luciferin substrate
Luciferase 1000 Assay System (Promega, USA) prior to
the measurement of luciferase activity using a Sirius
luminometer (Berthold, Australia). Comparisons between
the three means were analyzed using Student’s t-test at a
significance level of 5%. The cells were also harvested in
lysis buffer (50 mM Tris–HCl [pH 7.4], 150 mM NaCl, 1%
Triton X-100, 1 mM EDTA, 1 mM dithiothreitol, 1 mM
sodium fluoride, 0.2 mM sodium orthovanadate, 10 mM
β-glycerolphosphate, and protease inhibitor cocktail Mini
complete Roche®) for a western blot analysis, as described
above.
eIF3L overexpression was also performed in Vero cells
to better examine the alterations in the kinetics of viral
replication. For these assays, Vero cells were transfected
with the pCDNAFlag-eIF3L plasmid or a control using
the Turbofect transfection reagent (ThermoScientific) at
a ratio of 1:3, essentially as described by the manufac-
turer. At 24 h after transfection, the cells were counted
and infected with YFV 17D at an M.O.I. of 1 for 2 h (37°C).
The inoculum was then removed, washed 3× with 1× PBS
and replaced with maintenance medium. The supernatants
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extracted using the TRIzol reagent (Invitrogen) as described
by the manufacturer. Real-time PCR reactions were per-
formed using YF-specific primers (5’-TTGAACTACAT
GAGCCCACATC-3′ (forward) and 5′-CATAAGTCACTA
CCTGCCCCG-3′ (reverse) and the Fast SYBR Green
Master Mix (Applied Biosystems) for viral copy number
quantification.
Construction of pseudotyped lentiviral particles
For lentiviral pseudotyped particle (pp) production,
pLKO.1-eIF3L shRNA1 or pLKO.1-eIF3L shRNA2 was
co-transfected with the pCI-VSVG and p-CMV plasmids
into HEK-293T cells. The supernatant containing the
lentivirus particles was harvested to determine the viral
titer. The control vector pLKO.1-puro (Cat. # SHC001,
Sigma) and negative control shRNA (Cat. # SHC002,
Sigma) were used as the controls.
Knock-down experiments using shRNA and infection
assays
HEK-293T cells were infected with pseudotyped lentiviral
particles at an M.O.I. of 0.1 for 2 h. The infected cells were
washed with PBS and incubated in DMEM medium
supplemented with 1% FCS for 72 h in the presence of 5%
CO2. The viral RNA copy number was determined using
real-time PCR analysis, as described above. The cell super-
natants were harvested, and RNA was isolated using the
viral RNA isolation kit (HiSpeed Plasmid Midi Kit, Qiagen).
The cells were also harvested in lysis buffer (50 mM Tris–
HCl [pH 7.4], 150 mM NaCl, 1% Triton X-100, 1 mM
EDTA, 1 mM dithiothreitol, 1 mM sodium fluoride,
0.2 mM sodium orthovanadate, 10 mM β-glycerolphosphate,
and protease inhibitor cocktail Mini complete Roche®) for
a western blot analysis, as described above.
Plaque reduction assay
Vero cells were plated in 6-well microplates (4 × 105 cells/
well) and transfected with pCDNAFlag-eIF3L plasmid
using the Lipofectamine™ 2000 reagent (Invitrogen, USA)
according to the manufacturer’s recommendations. The
empty vector was used as a negative control. After 24 h of
transfection, the cells were infected with 50 PFU of YFV
17DD for 2 h at 37°C for adsorption. The monolayer was
washed with PBS and overlaid with MEM medium + 1%
carboxymethylcellulose (CMC, Sigma, Brazil) for 5 days
at 37°C in the presence of 5% CO2. The maintenance
medium was then removed, and the cells were fixed and
stained with crystal violet. The plaques were counted and
compared to the controls.
Effect of eIF3L overexpression on cell translation
To determine the effect of eIF3L overexpression on transla-
tion, HeLa cells were plated in 96-well microplates (1.5 ×104 cells/well) and cotransfected with pCDNAFlag-eIF3L
and pGL3 promoter plasmids at different concentrations.
After 48 h, the cells were lysed, and the supernatant was
used for luciferase activity assays.
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